RxDoctor Payments Data

Sara Hashemian, MD

Internal Medicine · Ann Arbor, MINPI 1427054006

Payments from drug & device makers

$1,290in general payments, 2019–2025

Across 84 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$311
  • Novo Nordisk$193
  • Pfizer$142
  • Novartis$117
  • Amgen$103
  • Merck$63
  • plus $362 from 12 others

What the payments were for

  • Food & beverage$1,285100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,290 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$81,392
Medicare patients
352
Services billed
2,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$164,192
OzempicSemaglutide98$158,485
EliquisApixaban140$146,669
MyrbetriqMirabegron85$72,348
RybelsusSemaglutide38$67,738
MounjaroTirzepatide42$59,935
XareltoRivaroxaban28$38,413
JanuviaSitagliptin Phosphate27$34,942
Breo ElliptaFluticasone/Vilanterol37$31,460
Mirabegron ErMirabegron36$29,127
TrulicityDulaglutide14$26,998
TradjentaLinagliptin19$25,453
Spiriva RespimatTiotropium Bromide23$22,959
FarxigaDapagliflozin Propanediol21$18,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$15,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$193$226,223136 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$50$212,605193 claims
PfizerEliquis$142$146,669140 claims
Lilly USA, LLCMounjaro, Trulicity$50$86,93356 claims
Astellas Pharma US IncMyrbetriq$23$72,34885 claims
GSKBreo Ellipta, Trelegy Ellipta$30$46,78550 claims
Johnson & JohnsonXarelto$311$38,41328 claims
MerckJanuvia$63$34,94227 claims
AstraZenecaFarxiga$17$18,98721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →